Familial Mediterranean Fever — Structured Data
AI-optimized single page. All data for Familial Mediterranean Fever in dense, structured format. Last updated: 2026-03-30.
View interactive disease hub · View all sources
Key Statistics
- Total reported cases
- Unknown
- Mean onset age
- 10 years
- Onset range
- 1–40 years
- Sex ratio (M:F)
- 1.2:1
- Diagnostic delay
- ~7 years
- Discovered
- 1945 (Sheppard Siegal)
- Prevalence
- <1/1,000,000
- Classification
- autoinflammatory, monogenic
- Pathophysiology
- well understood
- Treatment status
- effective treatment available
- Genetic basis
- well characterized
- Aliases
- FMF, Familial Paroxysmal Polyserositis, Periodic Disease, Benign Paroxysmal Peritonitis, Siegal-Cattan-Mamou Disease
Symptoms (10)
| Symptom | Frequency | Severity | Category | Description |
|---|---|---|---|---|
| Recurrent fever | 93% | cardinal | systemic | Fever typically 38-40C, lasting 12-72 hours. Self-limited. Occurs with attacks of serositis. Attack frequency ranges from several times per week to once per year. |
| Peritonitis (abdominal pain) | 94% | cardinal | gastrointestinal | Sterile peritonitis with acute abdominal pain mimicking surgical abdomen. Most common feature — present in 93.7% of Turkish cohort. Pain diffuse or localised, with rebound tenderness. Resolves spontaneously in 1-3 days. Can lead to unnecessary appendectomies. |
| Pleuritis (chest pain) | 31% | major | respiratory | Unilateral pleuritic chest pain, usually sharp and exacerbated by breathing. Present in approximately 31% of patients. Causes small pleural effusions. Resolves within 48 hours. |
| Arthritis / Arthralgia | 47% | major | musculoskeletal | Acute monoarthritis, typically large joints (knee, ankle, hip). Present in 47.4% of Turkish cohort. Significantly more frequent with M694V homozygosity (71%). Can be the sole manifestation. Usually non-destructive but protracted arthritis can cause joint damage. |
| Myalgia | 40% | major | musculoskeletal | Muscle pain present in approximately 39.6% of patients. Can manifest as exercise-induced myalgia or febrile myalgia syndrome. Protracted febrile myalgia is a severe variant lasting weeks. |
| Erysipelas-like erythema | 21% | minor | dermatologic | Distinctive painful, well-demarcated erythematous skin lesion, typically over the ankle or dorsum of the foot. Pathognomonic for FMF when present. Found in 20.9% of Turkish cohort. May be underrecognised. |
| Elevated acute phase reactants (CRP, ESR, SAA) | 95% | cardinal | laboratory | Massively elevated CRP, ESR, and SAA during attacks. Persistent subclinical elevation between attacks indicates ongoing inflammation and risk for amyloidosis. SAA is the most sensitive marker for subclinical inflammation. |
| Pericarditis | 1% | major | cardiovascular | Rare manifestation of FMF-associated serositis. Chest pain with pericardial effusion. Less common than pleuritis or peritonitis. |
| Splenomegaly | 30% | minor | gastrointestinal | Enlarged spleen reported in 10-60% of patients depending on the series. May be related to chronic inflammation or amyloid deposition. |
| Acute scrotal inflammation | 5% | major | genitourinary | Acute scrotal pain and swelling due to inflammation of the tunica vaginalis. More common in children. Can mimic testicular torsion, leading to unnecessary surgery. |
Molecular Pathway (10 molecules)
| Molecule | Role | Expression change | Evidence level | Targeted by | Explanation |
|---|---|---|---|---|---|
| Pyrin (MEFV) | Inflammasome sensor protein (mutated in FMF) | Gain-of-function mutations | established | Colchicine (indirect) | Pyrin is encoded by the MEFV gene and acts as an intracellular 'guard' sensor for RhoA GTPase activity. In healthy cells, pyrin is kept inactive by PKN1/PKN2-mediated phosphorylation and 14-3-3 protein binding. FMF mutations in the B30.2 domain impair this regulation, allowing pyrin inflammasome assembly upon dephosphorylation alone. This is the root cause of FMF. |
| IL-1β | Central effector cytokine | Elevated | established | Anakinra, Canakinumab, Rilonacept | IL-1beta is the key downstream cytokine driving all FMF clinical features. Produced by caspase-1 cleavage of pro-IL-1beta upon pyrin inflammasome activation. Drives fever, serositis, neutrophil recruitment, and acute-phase response. Confirmed by dramatic efficacy of IL-1 blockade (anakinra, canakinumab) in colchicine-resistant patients. |
| Caspase-1 | Inflammasome effector protease | Constitutively activated | established | — | Caspase-1 is recruited and activated by ASC within the pyrin inflammasome. Cleaves pro-IL-1beta and pro-IL-18 into mature forms. Also cleaves gasdermin D to trigger pyroptosis. Constitutively activated in FMF knock-in mouse macrophages. |
| ASC (PYCARD) | Inflammasome adaptor protein | Essential for pyrin inflammasome | established | — | ASC is the critical adaptor protein that bridges pyrin to caspase-1. The pyrin inflammasome is ASC-dependent — ASC-deficient mice crossed with FMF knock-in mice show complete ablation of inflammation. Pyrin's N-terminal PYD domain interacts with ASC's PYD domain. |
| RhoA GTPase | Upstream guard target | Normal (sensor target) | established | — | Pyrin functions as a guard for RhoA GTPase activity. When RhoA is inactivated by bacterial toxins, pyrin detects this as a danger signal. RhoA normally activates PKN1/PKN2 kinases that keep pyrin phosphorylated and inactive. The RhoA-PKN-pyrin axis is the central regulatory pathway disrupted in FMF. |
| PKN1/PKN2 | Pyrin phosphorylating kinases | Normal (regulatory) | established | — | PKN1 and PKN2 are serine-threonine kinases activated by RhoA. They directly phosphorylate pyrin at Ser208 and Ser242, promoting 14-3-3 binding and keeping pyrin inactive. FMF-associated mutant pyrin shows substantially decreased binding to PKN and 14-3-3 proteins. |
| 14-3-3 proteins | Pyrin inhibitory chaperones | Reduced binding to mutant pyrin | established | — | 14-3-3 epsilon and tau bind to phosphorylated pyrin (at Ser208/Ser242), preventing inflammasome assembly. This binding is substantially decreased in FMF-associated mutant pyrin, contributing to constitutive inflammasome activation. |
| IL-18 | Secondary inflammasome cytokine | Elevated | moderate | — | IL-18 is cleaved from its pro-form by caspase-1 alongside IL-1beta. Contributes to the inflammatory cascade in FMF attacks but is less well-studied than IL-1beta as a therapeutic target. |
| Gasdermin D | Pyroptosis executor | Cleaved/activated | moderate | — | Gasdermin D is cleaved by caspase-1 during pyrin inflammasome activation. The N-terminal fragment forms pores in the plasma membrane, leading to pyroptosis (inflammatory cell death) and further IL-1beta/IL-18 release. Contributes to the amplification of FMF inflammatory attacks. |
| Serum Amyloid A (SAA) | Acute-phase reactant and amyloid precursor | Elevated | established | Colchicine, IL-1 blockers (indirect) | SAA is produced by the liver in response to IL-1beta and IL-6 during FMF attacks. Persistently elevated SAA during remission periods (subclinical inflammation) is the precursor to AA amyloidosis. Median SAA >155 mg/L confers 17.7x relative risk of death. SAA is the key biomarker for monitoring disease control. |
Genetic Findings (6)
| Gene | Variant | Type | Frequency in disease | Significance | Also found in |
|---|---|---|---|---|---|
| MEFV | M694V (c.2080A>G, p.Met694Val) | germline | ~40% of disease alleles (most common) | The most common and most severe FMF mutation. Located in exon 10 (B30.2/SPRY domain). Homozygosity associated with earliest onset, highest attack frequency, most arthritis, and greatest risk of AA amyloidosis. | — |
| MEFV | M680I (c.2040G>A/C, p.Met680Ile) | germline | ~11% of disease alleles | Third most common FMF mutation. Located in exon 10. Homozygosity or compound heterozygosity with M694V associated with severe disease. M680I/M694V combination produces severe phenotype. | — |
| MEFV | V726A (c.2177T>C, p.Val726Ala) | germline | ~14% of disease alleles | Second most common FMF mutation. Located in exon 10. Heterozygosity generally associated with milder phenotype. However, V726A-E148Q complex allele can be severe. | — |
| MEFV | E148Q (c.442G>C, p.Glu148Gln) | germline | ~3% of disease alleles (controversial pathogenicity) | Located in exon 2. Highly controversial — debated whether pathogenic variant or benign polymorphism. Extremely high frequency in general population. When part of a complex allele with V726A, significantly increases disease severity. | — |
| MEFV | M694I (c.2082G>A/C, p.Met694Ile) | germline | ~3% of disease alleles | Located in exon 10. Fifth founder mutation. Homozygosity associated with severe disease. M694I/M694I genotype identified as a specific risk factor for AA amyloidosis in Algerian patients. | — |
| SAA1 | SAA1 alpha/alpha genotype | germline | Modifier (not causative) | The SAA1 alpha/alpha genotype is associated with a sevenfold increase in incidence of renal amyloidosis, especially in patients homozygous for M694V. SAA1 beta and gamma alleles appear protective against amyloidosis. | AA amyloidosis (various causes) (Risk modifier) |
Treatment Evidence Matrix (6 treatments)
| Drug | Mechanism | Route | Response rate | Onset | IgM effect | Line | Explanation |
|---|---|---|---|---|---|---|---|
| Colchicine | Microtubule disruption; reduces leukocyte motility and phagocytosis | Oral, 1-2 mg/day (adults), 0.5-1 mg/day (children) | ~95% (attack prevention) | Days-weeks (prophylactic) | Normalises SAA/CRP in most patients | 1st | Cornerstone lifelong treatment since 1972. Three seminal 1974 RCTs established efficacy. Prevents attacks in ~95% of patients and prevents AA amyloidosis development. Paradoxically, FMF mutations render pyrin inflammasome activation insensitive to colchicine in vitro — clinical efficacy likely through effects on leukocyte motility, adhesion, and phagocytosis. Safe in pregnancy. ~5-10% of patients are resistant, ~5-10% are intolerant (GI side effects). |
| Anakinra | IL-1 receptor antagonist | SC 100mg daily | 76.5% complete response | 2-3 days | Normalises SAA/CRP | 2nd | EMA-approved for FMF. First-line biologic for colchicine-resistant or intolerant patients. RCT showed significant attack reduction (1.7 vs 3.5 attacks/month, P=0.037). Rapid and persistent suppression of symptoms. Complete response in 76.5% of patients in systematic review. Requires daily subcutaneous injection. |
| Canakinumab | Anti-IL-1beta monoclonal antibody | SC 150mg every 4-8 weeks | 67.5% complete response | Days-weeks | Normalises SAA/CRP | 2nd | FDA and EMA approved for FMF. Longer dosing interval than anakinra (every 4-8 weeks vs daily). Reduced attacks from 8.3 to 1.56 per 24 weeks (P<0.001) in one cohort. Effective after colchicine and/or anakinra failure. Preferred by 72.2% of clinicians for colchicine-resistant FMF in multinational survey. |
| Rilonacept | IL-1 trap (soluble decoy receptor) | SC weekly | Moderate | Days-weeks | Reduces SAA/CRP | 3rd | Dimeric fusion protein that traps IL-1alpha and IL-1beta. Evaluated in clinical trials for FMF. Less commonly used than anakinra or canakinumab. Included in Cochrane systematic review of FMF treatments. |
| Tofacitinib | JAK inhibitor (JAK1/JAK3) | Oral 5-10mg twice daily | Promising (case series only) | Weeks | Suppresses inflammatory biomarkers | Investigational | JAK inhibitor showing promise in colchicine-resistant FMF. Three independent case series (6 patients total) reported marked suppression of inflammatory biomarkers and sustained clinical remission. Oral administration is an advantage. Larger controlled trials needed. |
| Tocilizumab | Anti-IL-6 receptor monoclonal antibody | IV or SC | Under investigation | Weeks | Reduces SAA/CRP via IL-6 blockade | Investigational | Phase III multicenter RCT evaluating efficacy in colchicine-resistant/intolerant FMF. Targets IL-6, which drives SAA production and systemic inflammation. Could be particularly relevant for preventing AA amyloidosis. Results pending. |
Diagnostic Criteria
Tel-Hashomer (Livneh) Criteria (1997)
Sensitivity: >95% · Specificity: >97%
Major criteria (all required)
- Recurrent febrile episodes accompanied by peritonitis, synovitis, or pleuritis
- AA amyloidosis with no predisposing disease
- Favorable response to continuous colchicine treatment
Minor criteria (2+ required)
- Recurrent febrile episodes
- Erysipelas-like erythema
- FMF in a first-degree relative
Definite FMF requires ≥2 major criteria, or 1 major + ≥2 minor criteria. Probable FMF requires 1 major + 1 minor. The most widely used criteria in adult populations. Supportive criteria include elevated acute-phase reactants during attacks, pathergy-positive skin test, and favorable colchicine response.
Eurofever/PRINTO Classification Criteria (2019)
Sensitivity: 85-89% · Specificity: 94-100%
Major criteria (all required)
- Presence of confirmatory MEFV genotype (homozygous or compound heterozygous pathogenic variants)
- Duration of episodes 1-3 days
- Abdominal pain
- Chest pain
- Arthritis (mono or oligo)
Minor criteria (1+ required)
- Eastern Mediterranean ethnicity
- Family history of FMF
First evidence-based classification criteria for hereditary recurrent fevers. Patients with confirmatory genotype need only 1 clinical criterion. Patients without confirmatory genotype need at least 2 clinical criteria from: episode duration 1-3 days, abdominal pain, chest pain, arthritis. Developed from the Eurofever international registry.
Yalcinkaya-Ozen (Pediatric) Criteria (2009)
Sensitivity: 86.5% · Specificity: 93.6%
Major criteria (all required)
- Fever: axillary temperature >38°C, duration 6-72 hours, ≥3 attacks
- Abdominal pain: duration 6-72 hours, ≥3 attacks
- Chest pain: duration 6-72 hours, ≥3 attacks
- Arthritis: duration 6-72 hours, ≥3 attacks, oligoarthritis
- Family history of FMF
Minor criteria (0+ required)
Requires ≥2 of the 5 criteria for diagnosis. Specifically designed for pediatric populations. Higher specificity than Tel-Hashomer in children. Does not require genetic testing.
Differential Diagnoses (8)
| Condition | Key distinction | Shared features |
|---|---|---|
| TNF Receptor-Associated Periodic Syndrome (TRAPS) | Attacks last 1-4 weeks (much longer than FMF's 1-3 days). TNFRSF1A mutations. Migratory myalgia and periorbital edema are characteristic. | Recurrent fever, Serositis, Elevated acute-phase reactants, Autosomal dominant inheritance, Risk of AA amyloidosis |
| Cryopyrin-Associated Periodic Syndromes (CAPS) | Urticarial rash is characteristic (not seen in FMF). NLRP3 mutations. Cold-triggered episodes in FCAS subtype. Sensorineural hearing loss in MWS/NOMID. | Recurrent fever, IL-1β driven inflammation, Responds to IL-1 blockade, Elevated CRP/SAA |
| Mevalonate Kinase Deficiency (MKD/HIDS) | Elevated serum IgD (>100 IU/mL) and urinary mevalonic acid. MVK gene mutations. Attacks often triggered by vaccination. Prominent cervical lymphadenopathy and oral ulcers. | Childhood onset, Recurrent febrile episodes, Abdominal pain, Arthralgia, Autosomal recessive |
| Adult-Onset Still's Disease (AOSD) | No genetic basis identified. Evanescent salmon-colored rash (not erysipelas-like). Markedly elevated ferritin with low glycosylated fraction. Quotidian fever pattern. | Recurrent fever, Serositis, Arthritis, Leukocytosis, Elevated CRP |
| Behçet Disease | Recurrent oral and genital ulcers are hallmark features. Pathergy test positive. Ocular involvement (uveitis) common. No MEFV mutations. HLA-B51 association. | Mediterranean population predilection, Recurrent episodes, Arthritis, Erythema nodosum-like lesions, Elevated acute-phase reactants |
| Systemic Lupus Erythematosus (SLE) | Positive ANA and anti-dsDNA antibodies. Complement consumption (low C3/C4). Photosensitive rash. Renal involvement with immune complex deposition, not amyloid. | Recurrent serositis, Arthritis, Fever, Renal involvement possible |
| Acute Appendicitis / Peritonitis | Single episode without spontaneous resolution. Surgical abdomen on examination. Imaging shows appendiceal inflammation or free air. No prior history of recurrent episodes. | Acute abdominal pain, Fever, Leukocytosis, Peritoneal signs |
| Schnitzler Syndrome | Chronic urticarial rash is obligate. Monoclonal IgM (or IgG) gammopathy required. Adult onset (>40 years typically). No MEFV mutations. | Recurrent fever, Bone pain, Elevated CRP/SAA, IL-1β driven, Responds to IL-1 blockade |
Hypotheses (5)
| Hypothesis | Domain | Status | Evidence score | Studies | Evidence for | Evidence against |
|---|---|---|---|---|---|---|
| Pyrin gain-of-function mutations lower the activation threshold of the pyrin inflammasome by impairing phosphorylation-dependent inhibition | pathogenesis | leading | 90/100 | 50 |
|
|
| Subclinical inflammation between attacks, not the attacks themselves, is the primary driver of long-term complications including AA amyloidosis | clinical | leading | 75/100 | 30 |
|
|
| Colchicine works in FMF primarily through anti-inflammatory effects on leukocyte function rather than direct pyrin inflammasome inhibition | treatment_mechanism | leading | 70/100 | 20 |
|
|
| High carrier frequency of MEFV mutations reflects heterozygote advantage against intracellular pathogens, particularly Yersinia pestis | evolutionary_genetics | leading | 65/100 | 15 |
|
|
| FMF heterozygotes can manifest clinical disease through a pseudo-dominant or dose-dependent mechanism involving gene modifiers and environmental triggers | genetics | emerging | 50/100 | 25 |
|
|
Open Questions (6)
- Why do up to 25% of clinically confirmed FMF patients have only one identifiable MEFV mutation?
Standard genetic testing covers exons 2, 3, 5, and 10. Second mutations may reside in regulatory regions, deep intronic sequences, or involve structural variants not detected by current methods. Alternatively, single-allele disease may represent a genuine pseudo-dominant mechanism. - What is the exact mechanism by which colchicine prevents FMF attacks despite mutant pyrin being insensitive to microtubule disruption?
Van Gorp et al. 2016 showed FMF mutations lift the obligatory requirement for microtubules in pyrin inflammasome activation, yet colchicine is ~95% effective clinically. The leading hypothesis involves leukocyte motility and phagocytosis, but the precise molecular targets are unclear. - Can biomarkers predict which patients will develop AA amyloidosis despite colchicine treatment?
AA amyloidosis remains the most feared complication. Known risk factors include M694V homozygosity, SAA1 alpha/alpha genotype, and persistently elevated SAA. However, some compliant patients still develop amyloidosis, and there is no validated predictive model. - What are the optimal treatment strategies for colchicine-resistant FMF beyond IL-1 blockade?
5-10% of FMF patients are colchicine-resistant and some fail IL-1 blockers as well. JAK inhibitors (tofacitinib) and IL-6 blockade (tocilizumab) are emerging options, but evidence is limited to case series and one phase III trial. No head-to-head comparisons exist. - Does heterozygote advantage against Yersinia pestis or other pathogens fully explain the high MEFV carrier frequencies?
Carrier rates of 1:3.5-5 in Mediterranean populations are remarkably high for a recessive disease. Mouse studies show FMF mutations confer Yersinia resistance, but human evidence is lacking. Genetic drift in founder populations is an alternative explanation. - What triggers individual FMF attacks in patients with stable underlying genetic susceptibility?
Attack frequency varies widely (several per week to once per year) and individual attacks appear to be triggered by environmental factors including stress, exercise, menstruation, and infections. The molecular link between these triggers and pyrin inflammasome activation is unknown.
Complications (6)
| Complication | Risk | Timeframe | Description | Monitoring |
|---|---|---|---|---|
| AA amyloidosis | 10-60% if untreated (varies by population and genotype) | Years of uncontrolled inflammation; typically after 10+ years of disease | The most feared complication of FMF. Chronic elevation of serum amyloid A (SAA) leads to deposition of AA amyloid fibrils in kidneys and other organs. M694V homozygosity and SAA1 alpha/alpha genotype are major risk factors. Colchicine prophylaxis effectively prevents amyloidosis development, even in high-risk genotypes. | Serum amyloid A (SAA) levels every 3-6 months; urinalysis for proteinuria at every visit; 24-hour urine protein if proteinuria detected |
| Renal failure | End-stage renal disease in untreated amyloidosis patients | Progressive over years following amyloid deposition | Secondary to AA amyloid deposition in the kidneys. Presents initially as proteinuria, progresses to nephrotic syndrome, and eventually end-stage renal disease requiring dialysis or transplantation. Renal transplant outcomes are favorable if colchicine is maintained post-transplant. | Serum creatinine and eGFR every 3-6 months; urine protein-to-creatinine ratio; renal biopsy if nephrotic-range proteinuria develops |
| Adhesive peritonitis | Variable; increased with frequent abdominal attacks | Cumulative with recurrent peritoneal inflammation | Recurrent sterile peritonitis during FMF attacks can lead to peritoneal adhesions. May cause chronic abdominal pain, small bowel obstruction, and female infertility due to tubal adhesions. A frequent cause of unnecessary laparotomy before FMF is diagnosed. | Clinical assessment for chronic abdominal symptoms; imaging if obstruction suspected |
| Infertility | Elevated in both sexes if untreated | Reproductive years | In women, recurrent peritonitis causes pelvic adhesions and tubal damage. In men, amyloid deposition in the testes or chronic inflammation may impair spermatogenesis. Colchicine treatment restores fertility in most patients; colchicine is safe during pregnancy and does not need to be discontinued. | Reproductive counseling; fertility assessment if difficulty conceiving |
| Growth retardation in children | Common in undertreated pediatric patients | Childhood and adolescence | Chronic inflammation suppresses growth hormone axis and promotes catabolic state. Children with frequent attacks may fall below growth percentiles. Colchicine treatment typically restores normal growth velocity. Delayed puberty may also occur. | Regular growth charts and height velocity monitoring; bone age assessment if growth delay suspected |
| Splenomegaly | 10-60% depending on series | Variable; may develop with chronic disease | Splenic enlargement results from chronic inflammation and, in some cases, amyloid deposition. Usually asymptomatic but may cause left upper quadrant discomfort. Can be associated with cytopenias in severe cases. | Abdominal examination at follow-up visits; ultrasound if clinically palpable; complete blood count to monitor for hypersplenism |
Sources (36)
| Ref | Authors | Title | Journal | Year | Category | Type | Grade | Link |
|---|---|---|---|---|---|---|---|---|
| D1 | Ozen S, Batu ED, Demir S, et al. | EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update | Ann Rheum Dis | 2025 | diagnostics | clinical guideline | A | DOI |
| H3 | Recent Advances Group | Familial Mediterranean Fever; Recent Advances, Future Prospectives | Diagnostics | 2025 | reviews | narrative review | B | PubMed |
| G4 | Grattagliano V, et al. | Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis | Clin Exp Rheumatol | 2023 | treatment | systematic review | A | PubMed |
| D4 | Cochrane Collaboration | Interventions for reducing inflammation in familial Mediterranean fever | Cochrane Database Syst Rev | 2022 | treatment | systematic review | A | PubMed |
| G6 | Cetin P, et al. | Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to colchicine and/or anakinra treatment | Int J Rheum Dis | 2021 | treatment | cohort | B | PubMed |
| H2 | Ozen S | Update in familial Mediterranean fever | Curr Opin Rheumatol | 2021 | reviews | narrative review | B | DOI |
| G1 | Alghamdi M | Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review | Turk J Med Sci | 2020 | reviews | narrative review | B | DOI |
| H1 | Park YH, et al. | Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis | Nat Immunol | 2020 | genetics | basic research | A | DOI |
| B5 | Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I | The pyrin inflammasome in health and disease | Front Immunol | 2019 | pathophysiology | narrative review | B | DOI |
| C2 | Gattorno M, Hofer M, Federici S, et al. | Classification criteria for autoinflammatory recurrent fevers | Ann Rheum Dis | 2019 | diagnostics | diagnostic criteria | A | DOI |
| G3 | Lidar M, Yaqubov M, Giat E, et al. | Familial Mediterranean Fever (FMF): a single centre retrospective study in Amsterdam | Rheumatol Int | 2019 | epidemiology | cohort | B | PubMed |
| E2 | Shinar Y, Obici L, Gattorno M, et al. | Lack of clear and univocal genotype-phenotype correlation in familial Mediterranean fever patients: a systematic review | Rheumatology (Oxford) | 2018 | genetics | systematic review | B | DOI |
| F3 | Heilig R, Broz P | Function and mechanism of the pyrin inflammasome | Eur J Immunol | 2018 | pathophysiology | narrative review | B | DOI |
| G5 | Kucuksahin O, et al. | IL-1-blocking therapy in colchicine-resistant familial Mediterranean fever | Clin Exp Rheumatol | 2018 | treatment | cohort | B | PubMed |
| B3 | Ben-Zvi I, Kukuy O, Giat E, et al. | Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial | Arthritis Rheumatol | 2017 | treatment | RCT | A | DOI |
| F2 | Alghamdi M | Familial Mediterranean fever, review of the literature | Clin Rheumatol | 2017 | reviews | narrative review | B | DOI |
| B2 | Park YH, Wood G, Kastner DL, Chae JJ | Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS | Nat Immunol | 2016 | pathophysiology | basic research | A | DOI |
| B4 | Ozen S, Demirkaya E, Erer B, et al. | EULAR recommendations for the management of familial Mediterranean fever | Ann Rheum Dis | 2016 | diagnostics | clinical guideline | A | DOI |
| B6 | Van Gorp H, Sber P, Van Hauwermeiren F, et al. | Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation | Proc Natl Acad Sci USA | 2016 | pathophysiology | basic research | A | DOI |
| C3 | Demirkaya E, Saglam C, Turker T, et al. | Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers | J Rheumatol | 2016 | diagnostics | validation study | B | DOI |
| D2 | Demirkaya E, Erer B, Ozen S, Ben-Chetrit E | Efficacy and safety of treatments in familial Mediterranean fever: a systematic review | Rheumatol Int | 2016 | treatment | systematic review | A | DOI |
| D3 | van der Hilst JCH, Moutschen M, Breitscheidel L, et al. | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature | Biologics | 2016 | treatment | systematic review | B | PubMed |
| A5 | Ozen S, Bilginer Y | A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin | Nat Rev Rheumatol | 2014 | reviews | narrative review | B | DOI |
| G2 | Sari I, Birlik M, Kasifoglu T | Familial Mediterranean fever: an updated review | Eur J Rheumatol | 2014 | reviews | narrative review | B | PubMed |
| B1 | Chae JJ, Cho YH, Lee GS, et al. | Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice | Immunity | 2011 | pathophysiology | basic research | A | DOI |
| C1 | Yalcinkaya F, Ozen S, Ozcakar ZB, et al. | A new set of criteria for the diagnosis of familial Mediterranean fever in childhood | Rheumatology (Oxford) | 2009 | diagnostics | diagnostic criteria | B | DOI |
| A4 | Tunca M, Akar S, Onen F, et al. | Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study | Medicine (Baltimore) | 2005 | epidemiology | cohort | B | DOI |
| F1 | Ben-Chetrit E, Levy M | Familial Mediterranean fever and renal AA amyloidosis — phenotype-genotype correlation, treatment and prognosis | J Nephrol | 2003 | clinical | narrative review | B | PubMed |
| E3 | Giaglis S, Papadopoulos V, Kambas K, et al. | The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever | J Mol Med | 2002 | genetics | cohort | B | PubMed |
| E1 | Touitou I | The spectrum of familial Mediterranean fever (FMF) mutations | Eur J Hum Genet | 2001 | genetics | population genetics | B | DOI |
| A1 | International FMF Consortium | Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever | Cell | 1997 | genetics | gene discovery | A | DOI |
| A2 | French FMF Consortium | A candidate gene for familial Mediterranean fever | Nature Genetics | 1997 | genetics | gene discovery | A | DOI |
| A3 | Livneh A, Langevitz P, Zemer D, et al. | Criteria for the diagnosis of familial Mediterranean fever | Arthritis Rheum | 1997 | diagnostics | diagnostic criteria | B | DOI |
| A6 | Goldstein RC, Schwabe AD | Prophylactic colchicine therapy in familial Mediterranean fever: a controlled, double-blind study | Ann Intern Med | 1974 | treatment | RCT | A | DOI |
| A7 | Dinarello CA, Wolff SM, Goldfinger SE, et al. | Colchicine therapy for familial Mediterranean fever: a double-blind trial | N Engl J Med | 1974 | treatment | RCT | A | DOI |
| A8 | Zemer D, Revach M, Pras M, et al. | A controlled trial of colchicine in preventing attacks of familial Mediterranean fever | N Engl J Med | 1974 | treatment | RCT | A | PubMed |
Pathophysiology Narrative
FMF is driven by dysregulated activation of the pyrin inflammasome, a distinct innate immune complex that is ASC-dependent but NLRP3-independent (Chae et al. 2011). Pyrin functions as an intracellular 'guard' sensor that monitors the activity of RhoA GTPases — a mechanism analogous to the guard hypothesis in plant immunity.
In healthy cells, RhoA GTPases activate the serine-threonine kinases PKN1 and PKN2, which phosphorylate pyrin at Ser208 and Ser242. Phosphorylated pyrin binds 14-3-3 inhibitory chaperone proteins, keeping the inflammasome in an inactive state. This two-level regulatory system — phosphorylation plus microtubule-dependent spatial control — prevents inappropriate inflammasome assembly.
FMF-associated mutations, concentrated in the B30.2/SPRY domain encoded by exon 10, fundamentally alter this regulation. In mutant pyrin, dephosphorylation alone is sufficient to trigger inflammasome activation, bypassing the second safety check. Moreover, FMF mutations lift the obligatory requirement for microtubules in pyrin inflammasome activation (Van Gorp et al. 2016), meaning the inflammasome can assemble even when microtubules are disrupted.
Once activated, the pyrin inflammasome recruits ASC and activates caspase-1, which cleaves pro-IL-1beta and pro-IL-18 into their mature, biologically active forms. Caspase-1 also cleaves gasdermin D, forming membrane pores that lead to pyroptosis and further cytokine release. The resulting IL-1beta surge drives all cardinal features of FMF attacks: fever, peritonitis, pleuritis, arthritis, and the acute-phase response with massively elevated CRP and SAA.
Paradoxically, although FMF mutations render pyrin inflammasome activation insensitive to colchicine in vitro, colchicine remains highly effective clinically — likely through its effects on leukocyte motility, adhesion, and phagocytosis during inflammation rather than direct inflammasome inhibition.
Genetic Basis Narrative
FMF is caused by mutations in the MEFV gene on chromosome 16p13.3, which comprises 10 exons encoding the 781-amino-acid protein pyrin (also called marenostrin). The gene was simultaneously identified in 1997 by two independent groups: the International FMF Consortium (Cell 1997) and the French FMF Consortium (Nature Genetics 1997).
Over 300 sequence variants have been identified in MEFV, but five founder mutations account for approximately 70-80% of disease-associated alleles: M694V (~40%), V726A (~14%), M680I (~11%), E148Q (~3%), and M694I (~3%). Most pathogenic mutations cluster in exon 10, encoding the B30.2/SPRY domain critical for pyrin's regulatory interactions.
Genotype-phenotype correlations are well-established but not absolute. M694V homozygosity is associated with the most severe phenotype: earlier age of onset, more frequent attacks, higher rates of arthritis, and the greatest risk of AA amyloidosis. M680I and M694I homozygosity also confer severe disease. In contrast, V726A and E148Q heterozygosity correlate with milder presentations.
FMF is classically autosomal recessive, but the genetic picture is more complex than initially appreciated. Up to 25% of clinically confirmed FMF patients carry only one identifiable MEFV mutation, and some heterozygotes manifest a spectrum from classic to mild FMF. An autosomal dominant form (OMIM 134610) has been described with specific mutations. The carrier frequency in affected populations is remarkably high — 1 in 3.5 to 1 in 5 among Armenians, Iraqi Jews, Turks, and Arabs — far higher than expected for a recessive disease, suggesting possible heterozygote advantage, potentially conferring resistance to intracellular pathogens such as Yersinia pestis.